Kojic acid

SKU: orb1301405

Description

Kojic acid

Research Area

Cell Biology, Infectious Disease & Virology, Pharmacology & Drug Discovery, Protein Biochemistry, Signal Transduction

Key Properties

• CAS Number: 501-30-4
• MW: 142.11
• Purity: 98.00% (May vary between batches)
• Formula: C₆H₆O₄
• SMILES: OCC1=CC(=O)C(O)=CO1
• Target: Tyrosinase,CDK,Parasite,NF-κB
• Solubility: DMSO:158.33 mg/mL (1114.14 mM)

Bioactivity

• In Vivo:
  4 weeks after KA-topical formulation treatment of infected animals, a healing process was observed with a high production of collagen fibers and a decrease in parasite burden. The great potential of KA as an anti-leishmanial compound.
• In Vitro:
  Kojic acid(KA) (50 μg/mL) was found to decrease the growth by 62% (IC50 34 μg/mL) and 79% (IC50 27.84 μg/mL) of promastigotes and amastigotes in vitro, respectively. KA-treated amastigotes showed the presence of vesicles bodies into the flagellar pocket, and an intense intracellular vacuolization and swelling of the mitochondrion. During the in vitro interaction of parasites and the host cell, KA reverses the superoxide anions (O2-) inhibitory mechanism promoted by parasite.
• Cell Research:
  Amazonensis promastigotes (10^6 parasites/mL) were inoculated in a 24-well plate containing RPMI medium supplemented with 10% inactivated fetal bovine serum treated with different concentrations of KA and incubated at 25 °C for 5 days without medium replacement. Every 24 h after treatment, aliquots were harvested and the effect of Kojic acid on promastigotes growth was evaluated using a Neubauer chamber and compared with untreated parasites culture. The cultures were performed in triplicate.
• Animal Research:
  Animals (eight-week-old female Golden hamsters) were infected with 10^6 of L. amazonensis promastigotes/mL during the stationary growth phase with a maximum volume of 0.2 mL on both hind paws. Animals were separated in 3 groups: untreated (n = 5); KA-treated 100 mg/kg/day (n = 5) and KA vehicle (n = 5). KA topical formulation treatment was initiated after 5 weeks of infection. The KA formulation and vehicle was applied topically to all lesions once daily for 4 weeks. Control groups were also maintained in parallel. During the treatment period, the lesion size was measured weekly using a caliper. Width and height of both hind paws were used to calculate the lesion area (mm^2).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, inhibit, Kojic acid, Parasite, tyrosinase

Compound Identifiers

PubChem CID

3840